- Open Access
How levosimendan can improve renal function?
Critical Care volume 23, Article number: 331 (2019)
The original article was published in Critical Care 2017 21:253
In recent years, several studies have addressed the positive effects of levosimendan upon renal function. We sought to summarize the recent findings in order to understand by which mechanism levosimendan is improving renal function. In acute decompensated heart failure, levosimendan has an immediate renoprotective effect by increasing renal blood flow (RBF) through selective renal arterial and venous vasodilation . In a recent randomized controlled study (RCT) comparing dobutamine and levosimendan in cardio-renal syndrome (CRS), Fedele et al.  were able to reproduce the results of Chen et al.  by measuring RBF through the renal artery [1, 2]. Fedele et al. and Chen et al. found that levosimendan increased RBF [1, 2]. But increasing RBF alone is not enough. Levosimendan and dobutamine exerted differential effects on glomerular filtration ratio (GFR). Both inotropic agents induced a renal vasodilatory effect accompanied by an increase in RBF, but while dobutamine does not change GFR, levosimendan increases GFR significantly . Levosimendan preferentially causes a vasodilation of the afferent arterioles while dobutamine induces a balanced vasodilation of both afferent and efferent arterioles, thereby increasing RBF, while maintaining a constant glomerular filtration pressure . Obviously, an isolated increase in GFR could jeopardize oxygenation of the medulla, which is sensitive to ischemia, given the highly oxygen-demanding sodium reabsorption process. For levosimendan, however, this is less likely to occur because it causes a balanced increase in GFR and renal oxygen delivery, as shown by the maintained renal oxygen consumption and extraction . Last, a rise in central venous pressure (CVP) is an important predictor of renal dysfunction in heart failure patients . Elevated CVP will increase renal venous backpressure and thus decrease renal perfusion pressure and impair renal function . Compared to dobutamine, levosimendan could further reduce CVP and by this end improve renal function also, but this is not supported by the findings of Lannemyr et al. because both inotropic agents reduced CVP to a similar extent . In conclusion, it is too simplistic to rely upon RBF to expect an improvement in renal function. An increase in RBF has to be accompanied by an increase in GFR but not at the cost of medullary hypoxemia, which is not the case with levosimendan. Effects on the reduction of CVP might also play a role. Finally, luxurious oxygenation of the cortex as induced by dopamine and dobutamine is completely useless for the kidney function, and again, the puzzle of improving renal function is far more complex.
Availability of data and materials
Acute kidney injury
Randomized controlled study
Renal blood flow
Glomerular filtration ratio
Central venous pressure
Chen QH, Zheng RQ, Lin H, Shao J, Yu JQ, Wang HL. Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Crit Care. 2017;21(1):253. https://doi.org/10.1186/s13054-017-1848-1 Review.
Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281–8.
Lannemyr L, Ricksten SE, Rundqvist B, Andersson B, Bartfay SE, Ljungman C, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double blind controlled trial. J Am Heart Assoc. 2018;7(16):e008455. https://doi.org/10.1161/JAHA.117.008455.
Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Dopamine increases renal oxygenation: a clinical study in post-cardiac surgery patients. Acta Anaesthesiol Scand. 2010;54:183–90.
Chen X, Wang X, Honore PM, Spapen HD, Liu D. Renal failure in critically ill patients, beware of applying (central venous) pressure on the kidney. Ann Intensive Care. 2018;8(1):91. https://doi.org/10.1186/s13613-018-0439-x.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available at https://doi.org/10.1186/s13054-017-1848-1.
About this article
Cite this article
Honore, P.M., Gutierrez, L.B., Redant, S. et al. How levosimendan can improve renal function?. Crit Care 23, 331 (2019) doi:10.1186/s13054-019-2642-z